Corrigendum


† Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
‡ Eli Lilly & Company, Lilly Biotechnology Center, San Diego, CA 92121, USA

The authors regret that they erroneously left a key contributor of their recently published manuscript entitled ‘Development of a novel antibody to Calcitonin Gene-Related Peptide for the treatment of osteoarthritis-related pain’. The studies described in this article were the result of many years of work, across a number of divisions in their company.

The erroneously failed to include Dr Nisenbaum, who was instrumental in the design and enablement of Laser Doppler Imaging to demonstrate functionality of antibodies to CGRP in vivo during the early phases of this project.

The correct list of authors should read (with the missing author’s name underlined):


DOI of original article: http://dx.doi.org/10.1016/j.joca.2014.01.009

* Address correspondence and reprint requests to: R.J. Benschop, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

E-mail address: benschop_robert@lilly.com (R.J. Benschop).